Emerging data on calcium-channel blockers: The COHORT study

Clinical Cardiology

Volumn 26, Issue 2 SUPPL., 2003, Pages

  Zanchetti, Alberto ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Amlodipine; Edema; Essential hypertension; Lacidipine; Lercanidipine

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; LACIDIPINE; LERCANIDIPINE; VERAPAMIL;

ADULT; AGED; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; FEMALE; FLUSHING; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TACHYCARDIA; UNITED STATES;

EID: 0037311820     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960261406     Document Type: Conference Paper

References (14)

1. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757-764
2. Staessen JA, Thijs L, Birkenhager WH, Bulpitt CJ, Fagard R: Update on the systolic hypertension in Europe (Syst-Eur) trial. The Syst-Eur Investigators. Hypertension 1999;33:1476-1477
3. Liu L, Wang JG, Gong L, Liu G, Staessen JA: Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens 1998;16:1823-1829
4. Wang JG, Staessen JA, Gong L, Liu L: Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med 2000;160: 211-220
5. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (also available at: www.ama-assn.org/intemal). Arch Intern Med 1997; 157:2413-2446
6. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999;17:151-183
7. Messerli FH: Calcium antagonists in hypertension: From hemodynamics to outcomes. Am J Hypertens 2002;15(7 pt 2):94S-97S
8. Herbette LG, Gaviraghi G, Tulenko T, Mason RP: Molecular interaction between lacidipine and biological membranes. J Hypertens 1993;11(suppl 1):S13-S19
9. Herbette LG: Lipophilic design of dihydropyridine calcium channel blockers: Enhanced membrane properties. Presented at: Third European Meeting on Calcium Antagonists; October 29-31, 1997; Amsterdam, Netherlands
10. Herbette LG, Vecchiarelli M, Sartani A, Leonardi A: Lercanidipine: Short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties. Blood Press 1998;7(suppl 2):10-17
11. Rengo F, Romis L: Activity of lercanidipine in double-blind comparison with nitrendipine in combination treatment of patients with resistant essential hypertension. J Cardiovasc Pharmacol 1997;29 (suppl 2):S54-S59
12. De Giorgio LA, Orlandini F, Malasoma P, Zappa A: Double-blind, crossover study of lercanidipine versus amlodipine in the treatment of mild-to-moderate essential hypertension. Curr Therap Res 1999; 60:511-520
13. Fogari R, Malamani GD, Zoppi A, Preti P, Vanasia A, Rogari E, Mugellini A: Comparative effect of lercanidipine and nifedipine gastrointestinal therapeutic system on ankle volume and subcutaneous interstitial pressure in hypertensive patients: A double-blind, randomized parallel-group study. Curr Therap Res 2000;61: 850-862
14. Leonetti G,Magnani B, Pessina AC, Rappelli A, Trimarco B, Zanchetti A, on behalf of the COHORT Study Group: Tolerability of long-term treatment with lercanidipine vs. amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002;15;932-940